145 results on '"Kanate A"'
Search Results
2. High Seroprevalence of Severe Fever with Thrombocytopenia Syndrome Virus Infection among the Dog Population in Thailand
3. Decision-Making System in Tannery by Using Fuzzy Logic
4. Soft Pneumatic Actuator from 3D-Printed TPU: Fabrication and Grasping Force Characterization
5. Citric Acid Catalyst-Assisted Bioactive Glass with Hydrogen Peroxide for In Vitro Bioactivity and Biodegradability Using Sol-Gel Method
6. Updated Indications for Immune Effector Cell Therapy: 2023 Guidelines from the American Society for Transplantation and Cellular Therapy
7. Bacteriophage Bioengineering: A Transformative Approach for Targeted Drug Discovery and Beyond
8. Umbilical Cord Blood Transplantation
9. List of Contributors
10. Haploidentical Versus Matched Unrelated Donor Transplants Using Post-Transplantation Cyclophosphamide for Lymphomas
11. Pembrolizumab for patients with non-Hodgkin lymphoma: phase 1b KEYNOTE-013 study
12. Phase 1 Study Evaluating Pharmacokinetics and Tolerability of Ofatumumab Combined With Bendamustine in Patients With Indolent B‐Cell Non‐Hodgkin's Lymphoma
13. Haploidentical Versus Matched Unrelated Donor Transplants for Lymphomas Using Post-Transplant Cyclophosphamide: A Joint CIBMTR/EBMT Study
14. Anti-CD20–atezolizumab–polatuzumab vedotin in relapsed/refractory follicular and diffuse large B-cell lymphoma
15. Diffuse large B-cell lymphoma
16. A UHPLC-PDA method for the quantitative analysis of total amino acids in infant formula with microwave-assisted acid hydrolysis
17. Pre-existing cardiovascular disease increases risk of atrial arrhythmia and mortality in cancer patients treated with Ibrutinib
18. Haploidentical Vs. Matched Unrelated Donor Transplants Using Post-Transplant Cyclophosphamide for Lymphoma: A Joint CIBMTR/EBMT Study
19. Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide‐pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics
20. Standardizing Definitions of Hematopoietic Recovery, Graft Rejection, Graft Failure, Poor Graft Function, and Donor Chimerism in Allogeneic Hematopoietic Cell Transplantation: A Report on Behalf of the American Society for Transplantation and Cellular Therapy
21. Impact of anti‐anaerobic antibiotic activity on graft‐versus‐host disease in allogeneic hematopoietic stem cell transplant (HSCT) recipients at an institution that utilizes antibiotic cycling
22. Correction to: Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era
23. PRE-EXISTING CARDIOVASCULAR DISEASE INCREASES RISK OF ATRIAL ARRHYTHMIA IN CANCER PATIENTS TREATED WITH IBRUTINIB
24. Pre-Existing Cardiovascular Disease Increases Risk of Atrial Arrhythmia in Cancer Patients Treated with Ibrutinib
25. Correction to: Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era
26. Reduced Toxicity Conditioning Allogeneic Hematopoietic Cell Transplantation with Once Daily Intravenous Busulfan for Relapsed/Refractory Lymphoma – a Phase II Study
27. Identification and characterization of mutations responsible for the β-lactam resistance in oxacillin-susceptible mecA-positive Staphylococcus aureus
28. Association of mprF mutations with cross-resistance to daptomycin and vancomycin in methicillin-resistant Staphylococcus aureus (MRSA)
29. Prospective assessment of Clostridioides (formerly Clostridium) difficile colonization and acquisition in hematopoietic stem cell transplant patients
30. Novel Targeted Therapies for Chronic Lymphocytic Leukemia in Elderly Patients: A Systematic Review
31. Indications for Hematopoietic Cell Transplantation and Immune Effector Cell Therapy: Guidelines from the American Society for Transplantation and Cellular Therapy
32. Development of CRISPR-Cas13a-based antimicrobials capable of sequence-specific killing of target bacteria
33. Complete Genome Sequence of a Panton-Valentine Leukocidin-Negative Staphylococcus aureus Strain Isolated from a Patient with Pervasive Necrotizing Soft Tissue Infection
34. Pomalidomide, bortezomib, and dexamethasone (PVd) in lenalidomide (LEN)-pretreated relapsed refractory multiple myeloma: Subanalysis of patients with renal impairment in OPTIMISMM.
35. Eligibility Criteria for Patients Undergoing Allogeneic Hematopoietic Cell Transplantation
36. Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era
37. An Impact of population on Minor Irrigation Projects Warud Tahsil, Distrist Amravati, Maharashtra
38. Health-related quality-of-life results from the phase 3 OPTIMISMM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myeloma
39. Corrigendum: Composition and Diversity of CRISPR-Cas13a Systems in the Genus Leptotrichia
40. Comparison of Clofarabine-Based Regimens Versus Etoposide Plus Mitoxantrone as Salvage Chemotherapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia
41. Composition and Diversity of CRISPR-Cas13a Systems in the Genus Leptotrichia
42. Relationship of physical function to outcomes in autologous hematopoietic stem cell transplantation.
43. Development of CRSIPR-Cas13a-based antimicrobials capable of sequence-specific killing of target bacteria
44. Who is the best relative? Optimizing haploidentical donor transplantation in lymphoma
45. Impact of T Cell Dose on Outcome of T Cell-Replete HLA-Matched Allogeneic Peripheral Blood Stem Cell Transplantation
46. Lower Graft-versus-Host Disease and Relapse Risk in Post-Transplant Cyclophosphamide–Based Haploidentical versus Matched Sibling Donor Reduced-Intensity Conditioning Transplant for Hodgkin Lymphoma
47. Composition and Diversity of CRISPR-Cas13a systems in the genus Leptotrichia
48. Venetoclax for Refractory Myeloid Sarcoma
49. Comparison of Graft Acquisition and Early Direct Charges of Haploidentical Related Donor Transplantation versus Umbilical Cord Blood Transplantation
50. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.